|Videos|July 20, 2021
Investigating Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD
Author(s)Adam Sperling, MD, PhD
The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed reasons to evaluate cellular therapy in multiple myeloma.
Advertisement
This content originally appeared on our sister site, OncLive.
OncLive spoke with Adam Sperling, MD, PhD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, about the rationale to evaluate cellular therapy in multiple myeloma.
Sperling discussed how the disease biology of multiple myeloma has demonstrated clear involvement with the immune system, and immune escape is an important feature of the malignancy. As such, immune- and cellular-based therapies have been a cornerstone of treatment in this setting, Sperling adds.
In addition, myeloma plasma cells express BCMA almost universally, Sperling says. Moreover, BCMA is not present on normal cells, making it an optimal target for therapies, Sperling concludes.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025
Advertisement
Advertisement